drugset / Trial / NCT01763606
Enoxaparin Versus Aspirin in Patients With Cancer and Stroke
Completed
20 enrolled
Memorial Sloan Kettering Cancer Center
New York Presbyterian Hospital · collabWeill Medical College of Cornell University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with cancer who develop stroke are at high risk for future strokes or other clotting events. These patients are routinely treated with medicines that thin their blood, including enoxaparin or aspirin. However, it is unclear which medicine is best and whether these medicines can be adequately studied in a clinical trial. The purpose of this Phase I/II study is to determine if a clinical trial of different blood thinners in patients with cancer and stroke is possible. In addition, the study aims to compare the effects, good and/or bad, of enoxaparin with those of aspirin on patients with cancer and recent stroke.
Timeline
- Start
- 2012-12-18
- Primary completion
- 2019-04-03
- Completion
- 2019-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | Oral |
| Subject | Enoxaparin sodium | Other / unclassified | 1 mg/kg | Subcutaneous |
Indications
No indication recorded.